Surmodics introduces immunoassay stabiliser StabilBlock

1 August 2016 (Last Updated August 1st, 2016 18:30)

US-based in-vitro diagnostics (IVD) company Surmodics has introduced its immunoassay stabiliser, StabilBlock, to inhibit non-specific binding to enhance immunoassay signal-to-noise ratios.

US-based in-vitro diagnostics (IVD) company Surmodics has introduced its immunoassay stabiliser, StabilBlock, to inhibit non-specific binding to enhance immunoassay signal-to-noise ratios.

The immunoassay stabiliser, which is a part of the company's in-vitro diagnostics products, preserves the conformation and activity of dried proteins on a range of surfaces while securing the performance of antibodies and antigens over a long duration.

The reagents induce a blocking mechanism which reduces non-specific binding of interfering proteins which thereby increases the assay sensitivity.

"We recognise that each assay has its own blocking requirements and our expanded portfolio of Immunoassay Stabilisers will enable assay developers to achieve the best results for each application."

Surmodics IVD vice-president and general manager Joe Stich said: “As part of our commitment to being the premier provider of IVD assay components to improve performance and manufacturability of immunoassays, we continue to advance our offerings to meet the needs of our customers.

“We recognise that each assay has its own blocking requirements and our expanded portfolio of Immunoassay Stabilisers will enable assay developers to achieve the best results for each application.”

The Surmodics IVD products enhances the assay performance as well as the manufacturability of assays by reducing backgrounds, increasing signal generation and providing longer shelf lives for immunoassay production.

The immunoassay offers a choice of blocking mechanism to achieve optimal signal-to-noise ratios for each assay.

The introduction of StabilBlock enhances the company's portfolio of products featuring the StabilZyme, BioFX TMB and Assay Diluent.